- Home
- ENTA vs NMI Comparison
ENTA vs NMI Comparison
Compare ENTA & NMI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ENTA
- NMI
- Stock Information
- Founded
- ENTA 1995
- NMI 1988
- Country
- ENTA United States
- NMI United States
- Employees
- ENTA N/A
- NMI N/A
- Industry
- ENTA Biotechnology: Pharmaceutical Preparations
- NMI Trusts Except Educational Religious and Charitable
- Sector
- ENTA Health Care
- NMI Finance
- Exchange
- ENTA Nasdaq
- NMI Nasdaq
- Market Cap
- ENTA 109.0M
- NMI 96.9M
- IPO Year
- ENTA 2013
- NMI N/A
- Fundamental
- Price
- ENTA $5.09
- NMI $9.80
- Analyst Decision
- ENTA Buy
- NMI
- Analyst Count
- ENTA 4
- NMI 0
- Target Price
- ENTA $17.25
- NMI N/A
- AVG Volume (30 Days)
- ENTA 503.4K
- NMI 28.4K
- Earning Date
- ENTA 02-18-2025
- NMI 01-01-0001
- Dividend Yield
- ENTA N/A
- NMI 4.10%
- EPS Growth
- ENTA N/A
- NMI N/A
- EPS
- ENTA N/A
- NMI N/A
- Revenue
- ENTA $67,635,000.00
- NMI N/A
- Revenue This Year
- ENTA $8.11
- NMI N/A
- Revenue Next Year
- ENTA N/A
- NMI N/A
- P/E Ratio
- ENTA N/A
- NMI N/A
- Revenue Growth
- ENTA N/A
- NMI N/A
- 52 Week Low
- ENTA $4.71
- NMI $8.30
- 52 Week High
- ENTA $17.80
- NMI $10.05
- Technical
- Relative Strength Index (RSI)
- ENTA 38.07
- NMI 64.98
- Support Level
- ENTA $4.94
- NMI $9.54
- Resistance Level
- ENTA $5.31
- NMI $9.88
- Average True Range (ATR)
- ENTA 0.32
- NMI 0.11
- MACD
- ENTA 0.11
- NMI 0.02
- Stochastic Oscillator
- ENTA 39.05
- NMI 77.14
About ENTA Enanta Pharmaceuticals Inc.
Enanta Pharmaceuticals Inc is an American biotechnology company which uses robust, chemistry-driven approach and drug discovery capabilities to focus on the research and development of molecule drugs to cure viral infections and liver diseases. Uses virology and immunology method for curing the diseases. The targeted diseases are hepatitis C, hepatitis B, nonalcoholic steatohepatitis, and the respiratory syncytial virus. The novelty of company research is a specific direct-acting antiviral inhibitor against the hepatitis C virus. The company's inhibitors have been developed in collaboration with AbbVie. AbbVie markets the protease inhibitor, paritaprevir, while other inhibitors are in the pipeline.
About NMI Nuveen Municipal Income Fund Inc.
Nuveen Municipal Income Fund Inc is a diversified closed-end management investment company. Its investment objective is to provide current income exempt from regular federal income tax by investing in a portfolio of municipal obligations issued by state and local government authorities or certain U.S. territories.